Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau et al. · The Lancet · 2018
Cited by 1,709 works. doi:10.1016/s0140-6736(18)31999-8
Authors
- Ezra E.W. Cohen
- Denis Soulières
- Christophe Le Tourneau
- José Dinis
- Lisa Francesca Licitra
- Myung‐Ju Ahn
- Ainara Soria
- Jean‐Pascal Machiels
- Nicolas Mach
- Ranee Mehra
- Barbara Ann Burtness
- Pingye Zhang
- Jonathan D. Cheng
- Ramona F. Swaby
- Kevin Joseph Harrington
- Mirelis Acosta-Rivera
- Douglas R. Adkins
- Morteza Aghmesheh
- Myung‐Ju Ahn
- Mario Airoldi
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Toxicity and response criteria of the Eastern Cooperative Oncology Group
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- The Efficiency of Cox's Likelihood Function for Censored Data
- Comparative analysis of two rates
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer